Notably, as a therapeutic biomarker, PD-L1 immunohistochemistry has been approved by the FDA for predicting treatment outcomes in advanced NSCLC and bladder cancer (Gibney et al., 2016). The gene discussed is CD274; the disease is non-small cell lung carcinoma.